Tumour necrosis factor (TNF) inhibitors
Tumour necrosis factor (TNF) inhibitors are vital medications used in the treatment of various autoimmune diseases. Understanding their analysis and interpretation is crucial for effective patient care.
What is analysed?
TNF inhibitors analysis involves measuring the concentration of TNF inhibitor medications in a patient's bloodstream.
What does the result mean?
The result of TNF inhibitor analysis indicates the level of the medication present in the patient's system.
Why undergo the analysis?
The analysis is conducted to ensure that patients are receiving an adequate therapeutic dose of TNF inhibitors, monitor medication levels over time, and detect any potential toxicity or adverse effects.
When to undergo the analysis?
Patients typically undergo TNF inhibitor analysis before starting treatment, at regular intervals during treatment to monitor medication levels, and if there are concerns about treatment efficacy or adverse effects.
What sample is required?
Blood samples are required for TNF inhibitor analysis.
Is any prior preparation necessary?
Patients may be advised to avoid certain medications or foods before the blood draw, depending on the specific requirements of the laboratory.
How is it used?
TNF inhibitor analysis helps healthcare providers optimise treatment regimens, adjust medication dosages, and manage potential medication-related complications.
What are the normal values?
Normal values for TNF inhibitor concentration vary depending on the specific medication, dosage, and individual patient factors.
TNF Inhibitor Analysis reference table
| Medication | Therapeutic range |
| Infliximab | 3 - 7 μg/mL |
| Adalimumab | 5 - 8 μg/mL |
| Etanercept | 0.5 - 2 μg/mL |
What do altered values signify?
Altered TNF inhibitor levels may indicate suboptimal dosing, medication non-adherence, drug interactions, or the development of drug resistance, necessitating further evaluation and intervention.
This table provides reference ranges for therapeutic levels of commonly prescribed TNF inhibitors, aiding in the interpretation of analysis results and guiding clinical decision-making in autoimmune disease management.